BLT2 is a pro-tumorigenic mediator during cancer progression and a therapeutic target for anti-cancer drug development - PubMed (original) (raw)
. 2013 Aug 14;3(4):347-55.
eCollection 2013.
Affiliations
- PMID: 23977445
- PMCID: PMC3744015
BLT2 is a pro-tumorigenic mediator during cancer progression and a therapeutic target for anti-cancer drug development
Nam-Kyu Cho et al. Am J Cancer Res. 2013.
Abstract
Cancer is a leading cause of death worldwide and has been linked to inflammation. Leukotriene B4 (LTB4) is synthesized from arachidonic acid via the 5-lipoxygenase pathway and is a potent chemoattractant for inflammatory cells. LTB4 was recently shown to be associated with the pathogenesis of inflammatory diseases, including cancer. Of the two known LTB4 receptors, BLT1 and BLT2, the biological roles of the low-affinity LTB4 receptor 2, BLT2, have only recently been elucidated. This review focuses on recent discoveries regarding BLT2 and its roles in cancer progression and the downstream signaling mechanisms of the BLT2-linked signaling cascade in cancer cells. We believe that these findings will facilitate the development of new cancer treatments.
Keywords: Leukotriene B4 receptor 2 (BLT2); NADPH oxidase; cancer progression; leukotriene B4; nuclear factor-kB; reactive oxygen species.
Figures
Figure 1
Schematic of LTB4 Biosynthesis. When a cell is activated, the increase in the intracellular Ca2+ concentration triggers the translocation of cPLA2 and 5-LOX to the nuclear membrane. Free arachidonic acid released by cPLA2 is metabolized to LTA4 and LTB4 via 5-LOX and LTA4H, respectively.
Figure 2
A Comprehensive Overview of BLT2 Signaling Pathways. For details, see text.
Similar articles
- Leukotriene B4 enhances the activity of nuclear factor-kappaB pathway through BLT1 and BLT2 receptors in atherosclerosis.
Sánchez-Galán E, Gómez-Hernández A, Vidal C, Martín-Ventura JL, Blanco-Colio LM, Muñoz-García B, Ortega L, Egido J, Tuñón J. Sánchez-Galán E, et al. Cardiovasc Res. 2009 Jan 1;81(1):216-25. doi: 10.1093/cvr/cvn277. Epub 2008 Oct 13. Cardiovasc Res. 2009. PMID: 18852255 - A turn on and a turn off: BLT1 and BLT2 mechanisms in the lung.
Watanabe M, Machida K, Inoue H. Watanabe M, et al. Expert Rev Respir Med. 2014 Aug;8(4):381-3. doi: 10.1586/17476348.2014.908715. Epub 2014 Apr 18. Expert Rev Respir Med. 2014. PMID: 24742066 - Therapeutic target of leukotriene B4 receptors, BLT1 and BLT2: Insights from basic research.
Nakamura M, Shimizu T. Nakamura M, et al. Biochimie. 2023 Dec;215:60-68. doi: 10.1016/j.biochi.2023.06.014. Epub 2023 Jul 7. Biochimie. 2023. PMID: 37423557 Review. - Leukotriene B4 receptors BLT1 and BLT2: expression and function in human and murine mast cells.
Lundeen KA, Sun B, Karlsson L, Fourie AM. Lundeen KA, et al. J Immunol. 2006 Sep 1;177(5):3439-47. doi: 10.4049/jimmunol.177.5.3439. J Immunol. 2006. PMID: 16920986 - Recent advances in function and structure of two leukotriene B4 receptors: BLT1 and BLT2.
Nakamura M, Shimizu T. Nakamura M, et al. Biochem Pharmacol. 2022 Sep;203:115178. doi: 10.1016/j.bcp.2022.115178. Epub 2022 Jul 16. Biochem Pharmacol. 2022. PMID: 35850310 Review.
Cited by
- The Role and Regulation of Thromboxane A2 Signaling in Cancer-Trojan Horses and Misdirection.
Ashton AW, Zhang Y, Cazzolli R, Honn KV. Ashton AW, et al. Molecules. 2022 Sep 22;27(19):6234. doi: 10.3390/molecules27196234. Molecules. 2022. PMID: 36234768 Free PMC article. Review. - Leukotriene B4 receptor 2 correlates with prognosis and immune infiltration in clear cell renal cell carcinoma.
Yuan X, He Y, Luo C, Wang W. Yuan X, et al. Invest New Drugs. 2022 Apr;40(2):232-244. doi: 10.1007/s10637-021-01174-7. Epub 2021 Oct 11. Invest New Drugs. 2022. PMID: 34633577 - The yin and yang of leukotriene B4 mediated inflammation in cancer.
Jala VR, Bodduluri SR, Satpathy SR, Chheda Z, Sharma RK, Haribabu B. Jala VR, et al. Semin Immunol. 2017 Oct;33:58-64. doi: 10.1016/j.smim.2017.09.005. Epub 2017 Oct 2. Semin Immunol. 2017. PMID: 28982616 Free PMC article. Review. - Two distinct forms of human BLT2: long-form and short-form BLT2.
Wei JD, Kim JH. Wei JD, et al. Front Cell Dev Biol. 2023 Oct 26;11:1288373. doi: 10.3389/fcell.2023.1288373. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 37954206 Free PMC article. Review. - Neutrophils support lung colonization of metastasis-initiating breast cancer cells.
Wculek SK, Malanchi I. Wculek SK, et al. Nature. 2015 Dec 17;528(7582):413-7. doi: 10.1038/nature16140. Epub 2015 Dec 9. Nature. 2015. PMID: 26649828 Free PMC article.
References
- Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, Moran A, Mulholland K, Nair MN, Naldi L, Narayan KM, Nasseri K, Norman P, O’Donnell M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope CA 3rd, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De Leon FR, Rosenfeld LC, Rushton L, Sacco RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstock MA, Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–2128. - PMC - PubMed
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674. - PubMed
- Dinarello CA. The paradox of pro-inflammatory cytokines in cancer. Cancer Metastasis Rev. 2006;25:307–313. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources